Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ECOR
SELLelectroCore, Inc. · Healthcare · United States · $51M · Avg Vol: $533K/d
COMPANY DESCRIPTION
electroCore, Inc. is a commercial-stage medical device company that develops and commercializes non-invasive vagus nerve stimulation therapies, primarily under the gammaCore brand. The company's competitive moat is its patented, non-invasive technology platform that offers a drug-free alternative for treating primary headaches and other autonomic nervous system disorders. electroCore operates as a pioneer and niche leader in the bioelectronic medicine sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.6M | 16.0M | 25.2M | 32.0M | 55.1% | 34.9M | 41.9M | 54.2M | 30.1% |
| EPS | -4.69 | -3.42 | -1.59 | -1.65 | — | -1.82 | -1.48 | -0.43 | — |
| Shares | 4.7M | 6.0M | 6.7M | 8.0M | +68.7% | 8.3M | — | — | — |
| Debt | 0.7M | 0.6M | 4.1M | 9.4M | 137.8% | 9.5M | — | — | — |
| Equity | 17.1M | 7.4M | 7.5M | -1.7M | -33.6% | — | — | — | — |
| Op CF | -16.6M | -14.7M | -6.9M | -8.2M | — | -6.8M | — | — | — |
| Inv CF | 0 | -0.2M | -8.5M | 3.9M | — | — | — | — | — |
| Fin CF | 0 | 7.5M | 8.4M | 7.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ECOR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ECOR | electroCore, Inc.(you) | $51M | 22 | SELL |
| ELUT | Elutia Inc. | $51M | 25 | SELL |
| LUNG | Pulmonx Corporation | $53M | 18 | STRONG SELL |
| ARAY | Accuray Incorporated | $53M | 18 | STRONG SELL |
| MDAI | Spectral AI, Inc. | $52M | 16 | STRONG SELL |
| COCH | Envoy Medical, Inc. | $51M | 14 | STRONG SELL |
| OM | Outset Medical, Inc. | $75M | 16 | STRONG SELL |
| LNSR | LENSAR, Inc. | $69M | 11 | STRONG SELL |
| AVH.AX | AVITA Medical, Inc. | $115M | 20 | SELL |
| HYPR | Hyperfine, Inc. | $95M | 13 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%